GSK secures expanded Japanese approval for Arexvy vaccine to cover at-risk adults under 50
GSK (NYSE:GSK) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved a label expansion for Arexvy, its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine.




_1401863_640x360_2500431939516-640x360.webp&w=3840&q=75)





_1401804_640x360_2500433475652-640x360.webp&w=3840&q=75)
_1401799_640x360_2500433475643-640x360.webp&w=3840&q=75)